Ketotifen in systemic mastocytosis—A response
✍ Scribed by KETTELHUT, B
- Book ID
- 119059936
- Publisher
- Elsevier Science
- Year
- 1991
- Tongue
- English
- Weight
- 112 KB
- Volume
- 87
- Category
- Article
- ISSN
- 1097-6825
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Six patients with documented systemic mast cell disease were enrolled in a 1-year, phase I study to determine the possible benefits of interferon alpha-2b (IFN-alpha). IFN-alpha therapy was begun at a dosage of 0.5 million units/day (MU/day) by subcutaneous injection and increased, as tolerated, to
6/155), high white cell number (13/155) (red cell unit) or low thrombocyte number (14/125) (thrombocyte unit). Summary: Donors with low hemoglobin levels have to be excluded from the blood donation service for 3 months. So, in theory haemoglobin concentration of all total blood units is suitable for